Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
KURA Stock Summary
Top 10 Correlated ETFs
KURA
In the News
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
Kura Oncology stock jumped another 20% on Tuesday: here's why
Kura Oncology Inc (NASDAQ: KURA) rallied close to 20% this morning after reporting positive preliminary data for a Phase 1 study of its Ziftomenib “in combination with standards of care”. Ziftomenib trial pushes Kura Oncology stock up The dose-escalation trial studied the combination in patients of acute myeloid leukemia.
Kura Oncology: Riding The Menin Hype Wave In AML Therapy
Kura Oncology is an oncology-focused biotech developing targeted therapies for various forms of cancer with high unmet need. Their pipeline includes ziftomenib for AML, with promising phase 2 results and a potential data readout in 2024. They are also developing tipifarnib for HRAS-mutated HNSCC, with breakthrough therapy designation and positive response rates in early trials.
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences.
Kura Oncology to Report Third Quarter 2023 Financial Results
SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2023 financial results after the close of U.S. financial markets on Thursday, November 2, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
What Makes Kura Oncology (KURA) a New Buy Stock
Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kura's Ziftomenib: The Swiss Army Knife In AML Therapy
Kura Oncology's lead candidate, ziftomenib, shows dual-functionality in treating NPM1-mutant AML and overcoming resistance mutations. Company's financials robust with $477M in liquid assets, offsetting a manageable monthly cash burn of $10.2M, providing a 46.8-month cash runway. Given the clinical promise of ziftomenib and strong financial footing, the stock presents an attractive risk-to-reward profile; "Buy" recommendation.
Kura Oncology, Inc. (KURA) Q2 2023 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice President, Investor Relations & Corporate Communications Troy Wilson - President & Chief Executive Officer Tom Doyle - Senior Vice President, Finance & Accounting Conference Call Participants Jonathan Chang - Leerink Partners Roger Song - Jefferies Peter Lawson - Barclays Li Watsek - Cantor Bijan Mekoba - Stifel Julian Harrison - BTIG Reni Benjamin - JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Q2 2023 Kura Oncology, Inc. Earnings Conference Call. At this time, all lines are in listen-only mode.
7 Best Cancer Stocks to Invest in Now
One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. There are many types of cancer, many of which have limited cure and treatment options.
KURA Financial details
KURA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.51 | -1.68 | -1.96 | -2.03 | -2.08 | |
Operating cash flow per share | -1.31 | -1.32 | -1.58 | -1.64 | -1.7 | |
Free cash flow per share | -1.31 | -1.36 | -1.59 | -1.65 | -1.71 | |
Cash per share | 5.65 | 11.93 | 7.81 | 6.54 | 5.79 | |
Book value per share | -5.08 | -5.7 | -6.53 | -8.49 | 5.43 | |
Tangible book value per share | 5.22 | 11.51 | 7.64 | 6.27 | 5.43 | |
Share holders equity per share | -5.08 | -5.7 | -6.53 | -8.49 | 5.43 | |
Interest debt per share | 0.19 | 0.29 | 0.11 | 0.21 | 0.17 | |
Market cap | 576.76M | 1.73B | 928.93M | 831.35M | 1.05B | |
Enterprise value | 558.12M | 1.42B | 845.13M | 793.57M | 1.03B | |
P/E ratio | -9.13 | -19.38 | -7.15 | -6.11 | -6.9 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -10.53 | -24.82 | -8.88 | -7.55 | -8.44 | |
PFCF ratio | -10.53 | -24.08 | -8.79 | -7.51 | -8.42 | |
P/B Ratio | -2.71 | -5.73 | -2.15 | -1.46 | 2.65 | |
PTB ratio | -2.71 | -5.73 | -2.15 | -1.46 | 2.65 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -8.27 | -15.48 | -6.44 | -5.67 | -6.26 | |
EV to operating cash flow | -10.19 | -20.38 | -8.08 | -7.21 | -8.27 | |
EV to free cash flow | -10.19 | -19.76 | -8 | -7.17 | -8.26 | |
Earnings yield | -0.11 | -0.05 | -0.14 | -0.16 | -0.14 | |
Free cash flow yield | -0.09 | -0.04 | -0.11 | -0.13 | -0.12 | |
Debt to equity | -0.04 | -0.05 | -0.02 | -0.02 | 0.03 | |
Debt to assets | 0.03 | 0.02 | 0.01 | 0.03 | 0.02 | |
Net debt to EBITDA | 0.28 | 3.38 | 0.64 | 0.27 | 0.12 | |
Current ratio | 15.39 | 24.49 | 23.26 | 18.56 | 12.26 | |
Interest coverage | -116.34 | -159.33 | -318.4 | -614.08 | -107.04 | |
Income quality | 0.87 | 0.78 | 0.8 | 0.81 | 0.82 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.03 | 0.01 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -11.19 | -2.06 | -0.82 | -0.2 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 13.11 | 14.7 | 16.95 | 19.7 | 15.95 | |
ROIC | 0.33 | 0.33 | 0.31 | 0.26 | -0.4 | |
Return on tangible assets | -0.26 | -0.14 | -0.24 | -0.3 | -0.34 | |
Graham Net | 5.1 | 11.25 | 7.39 | 6 | 5.11 | |
Working capital | 224.04M | 611.27M | 499.83M | 422.37M | 397.22M | |
Tangible asset value | 218.78M | 610.91M | 506.61M | 420.28M | 397.27M | |
Net current asset value | 216.41M | 600.99M | 494.85M | 410.4M | 380.82M | |
Invested capital | -0.04 | -0.05 | -0.02 | -0.02 | 0.03 | |
Average receivables | 127K | 15K | 0 | 0 | 1.4M | |
Average payables | 3.82M | 3.14M | 2.99M | 2.38M | 1.92M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 5.18K | 2.12K | 737.21 | 988.81 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.07 | 0.17 | 0.5 | 0.37 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.3 | 0.3 | 0.3 | 0.24 | -0.38 | |
Capex per share | 0 | -0.04 | -0.02 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0.02 | |
Net income per share | -0.49 | -0.45 | -0.53 | -0.5 | -0.55 | |
Operating cash flow per share | -0.39 | -0.52 | -0.37 | -0.38 | -0.44 | |
Free cash flow per share | -0.39 | -0.52 | -0.37 | -0.38 | -0.44 | |
Cash per share | 6.46 | 5.93 | 6.83 | 5.86 | 5.48 | |
Book value per share | -8.39 | -8.81 | -9.17 | 5.57 | 5.14 | |
Tangible book value per share | 6.2 | 5.78 | 6.93 | 5.57 | 5.14 | |
Share holders equity per share | -8.39 | -8.81 | -9.17 | 5.57 | 5.14 | |
Interest debt per share | 0.21 | 0.2 | 0.18 | 0.23 | 0.15 | |
Market cap | 841.16M | 836.57M | 738.43M | 704.44M | 1.11B | |
Enterprise value | 803.38M | 823.05M | 702.35M | 693.12M | 1.09B | |
P/E ratio | -6.31 | -6.75 | -4.97 | -4.56 | -6.5 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 875.67 | |
POCF ratio | -31.71 | -23.32 | -28.83 | -24.27 | -32.42 | |
PFCF ratio | -31.69 | -23.3 | -28.72 | -24.25 | -32.4 | |
P/B Ratio | -1.48 | -1.39 | -1.15 | 1.64 | 2.8 | |
PTB ratio | -1.48 | -1.39 | -1.15 | 1.64 | 2.8 | |
EV to sales | 0 | 0 | 0 | 0 | 859.83 | |
Enterprise value over EBITDA | -22.85 | -22.51 | -17.56 | -18.25 | -23.46 | |
EV to operating cash flow | -30.28 | -22.94 | -27.42 | -23.88 | -31.83 | |
EV to free cash flow | -30.27 | -22.92 | -27.32 | -23.86 | -31.81 | |
Earnings yield | -0.04 | -0.04 | -0.05 | -0.05 | -0.04 | |
Free cash flow yield | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | |
Debt to equity | -0.02 | -0.02 | -0.02 | 0.04 | 0.03 | |
Debt to assets | 0.03 | 0.03 | 0.03 | 0.04 | 0.02 | |
Net debt to EBITDA | 1.07 | 0.37 | 0.9 | 0.3 | 0.43 | |
Current ratio | 18.56 | 21.65 | 19.96 | 16.71 | 12.26 | |
Interest coverage | -154.42 | -101.02 | 103.37 | -95.55 | -118.69 | |
Income quality | 0.8 | 1.05 | 0.69 | 0.75 | 0.8 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 11.2 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 25.62 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | -0.01 | |
Capex to depreciation | -0.06 | -0.17 | -0.45 | -0.09 | -0.07 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 5.64 | |
Graham number | 9.64 | 9.48 | 10.48 | 7.91 | 8 | |
ROIC | 0.06 | 0.06 | 0.06 | -0.09 | -0.12 | |
Return on tangible assets | -0.07 | -0.07 | -0.08 | -0.08 | -0.1 | |
Graham Net | 5.93 | 5.48 | 6.67 | 5.29 | 4.84 | |
Working capital | 422.37M | 397.22M | 453.08M | 432.39M | 397.22M | |
Tangible asset value | 420.28M | 395.18M | 483.58M | 429.94M | 397.27M | |
Net current asset value | 410.4M | 385.66M | 465.82M | 416.08M | 380.82M | |
Invested capital | -0.02 | -0.02 | -0.02 | 0.04 | 0.03 | |
Average receivables | 0 | 0 | 0 | 0 | 1.4M | |
Average payables | 1.64M | 2.41M | 2.81M | 2.05M | 2.03M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 198.43 | |
Days payables outstanding | 669.76 | 1.44K | 987.46 | 734.17 | 967.29 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0.45 | |
Payables turnover | 0.13 | 0.06 | 0.09 | 0.12 | 0.09 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.06 | 0.05 | 0.06 | -0.09 | -0.11 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
KURA Frequently Asked Questions
What is Kura Oncology, Inc. stock symbol ?
Kura Oncology, Inc. is a US stock , located in San diego of Ca and trading under the symbol KURA
Is Kura Oncology, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $26. The lowest prediction is $26 and the highest is $26
What is KURA stock prediction ?
What is Kura Oncology, Inc. stock quote today ?
Kura Oncology, Inc. stock price is $21.62 today.
Is Kura Oncology, Inc. stock public?
Yes, Kura Oncology, Inc. is a publicly traded company.